Fujita N - Search Results

1

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.

Okada K, Araki M, Sakashita T, Ma B, Kanada R, Yanagitani N, Horiike A, Koike S, Oh-Hara T, Watanabe K, Tamai K, Maemondo M, Nishio M, Ishikawa T, Okuno Y, Fujita N, Katayama R. Okada K, et al. Among authors: fujita n. EBioMedicine. 2019 Mar;41:105-119. doi: 10.1016/j.ebiom.2019.01.019. Epub 2019 Jan 17. EBioMedicine. 2019. PMID: 30662002 Free PMC article.

2

Casein kinase 2-interacting protein-1, a novel Akt pleckstrin homology domain-interacting protein, down-regulates PI3K/Akt signaling and suppresses tumor growth in vivo.

Tokuda E, Fujita N, Oh-hara T, Sato S, Kurata A, Katayama R, Itoh T, Takenawa T, Miyazono K, Tsuruo T. Tokuda E, et al. Among authors: fujita n. Cancer Res. 2007 Oct 15;67(20):9666-76. doi: 10.1158/0008-5472.CAN-07-1050. Cancer Res. 2007. PMID: 17942896

3

Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.

Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Morishita D, et al. Among authors: fujita n. Cancer Res. 2008 Jul 1;68(13):5076-85. doi: 10.1158/0008-5472.CAN-08-0634. Cancer Res. 2008. PMID: 18593906

4

TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling.

Kurata A, Katayama R, Watanabe T, Tsuruo T, Fujita N. Kurata A, et al. Among authors: fujita n. Cancer Sci. 2008 Sep;99(9):1827-34. doi: 10.1111/j.1349-7006.2008.00874.x. Epub 2008 Jul 4. Cancer Sci. 2008. PMID: 18616680 Free PMC article.

5

PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation.

Tanaka H, Hoshikawa Y, Oh-hara T, Koike S, Naito M, Noda T, Arai H, Tsuruo T, Fujita N. Tanaka H, et al. Among authors: fujita n. Mol Cancer Res. 2009 Apr;7(4):557-69. doi: 10.1158/1541-7786.MCR-08-0197. Mol Cancer Res. 2009. PMID: 19372584

6

[Drug resistance mediated by survival- and growth-promoting signaling pathways].

Fujita N. Fujita N. Gan To Kagaku Ryoho. 2009 Apr;36(4):567-71. Gan To Kagaku Ryoho. 2009. PMID: 19381028 Japanese.

7

Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.

Katayama R, Koike S, Sato S, Sugimoto Y, Tsuruo T, Fujita N. Katayama R, et al. Among authors: fujita n. Cancer Sci. 2009 Nov;100(11):2060-8. doi: 10.1111/j.1349-7006.2009.01288.x. Epub 2009 Jul 17. Cancer Sci. 2009. PMID: 19673889 Free PMC article.

8

Modulation of Wnt signaling by the nuclear localization of cellular FLIP-L.

Katayama R, Ishioka T, Takada S, Takada R, Fujita N, Tsuruo T, Naito M. Katayama R, et al. Among authors: fujita n. J Cell Sci. 2010 Jan 1;123(Pt 1):23-8. doi: 10.1242/jcs.058602. J Cell Sci. 2010. PMID: 20016063

9

Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.

Morishita D, Takami M, Yoshikawa S, Katayama R, Sato S, Kukimoto-Niino M, Umehara T, Shirouzu M, Sekimizu K, Yokoyama S, Fujita N. Morishita D, et al. Among authors: fujita n. J Biol Chem. 2011 Jan 28;286(4):2681-8. doi: 10.1074/jbc.M109.092452. Epub 2010 Nov 9. J Biol Chem. 2011. PMID: 21062737 Free PMC article.

10

AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells.

Misawa A, Katayama R, Koike S, Tomida A, Watanabe T, Fujita N. Misawa A, et al. Among authors: fujita n. Oncol Res. 2010;19(1):23-33. doi: 10.3727/096504010x12828372551759. Oncol Res. 2010. PMID: 21141738

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,623 results

Search Page

Filters